Germline pathogenic variants in neuroblastoma patients are enriched in <i>BARD1</i> and predict worse survival

Jung Kim(Yale University), Sharon J. Diskin(Children's Hospital of Philadelphia), John M. Maris(Children's Hospital of Philadelphia), Javed Khan(Kent State University), Kristopher R. Bosse(Children's Hospital of Philadelphia), Rebecca Kaufman(Children's Hospital of Philadelphia), Jaime M. Guidry Auvil(National Institutes of Health), Zalman Vaksman(Children's Hospital of Philadelphia), Michael P. Randall(Dartmouth College), Jun S. Wei(Center for Cancer Research), Malwina Dymek(Children's Hospital of Philadelphia), Douglas R. Stewart(Cancer Genetics (United States)), Kara N. Maxwell(Philadelphia VA Medical Center), Gonzalo López(Icahn School of Medicine at Mount Sinai), Lance M. Farra(Children's Hospital of Philadelphia), Belynda Hicks(Frederick National Laboratory for Cancer Research), Ryan Hausler(Cancer Research Institute), Trevor J. Pugh(Boston Children's Hospital), Perry Evans(Children's Hospital of Philadelphia), Laura E. Egolf(National Cancer Institute), Maiah H. Dent(Yale University), Neil Menghani(Children's Hospital of Philadelphia), Håkon Håkonarson(Children's Hospital of Philadelphia), Karina L. Conkrite(Department of Embryology), Heena Desai(Cancer Research Institute), Arnavaz Danesh(University Health Network), Daniela S. Gerhard(United States Department of Health and Human Services), Kristina A. Cole(Children's Hospital of Philadelphia)
JNCI Journal of the National Cancer Institute
September 9, 2023
Cited by 28


Related Papers